Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

E-ISSN： 1873-4294|15|10|927-938

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.15, Iss.10, 2015-05, pp. : 927-938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting leucine-rich repeat kinase 2 in Parkinson's disease

By Chan Sharon L Angeles Dario C Tan Eng-King

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 12, 2013-12 ,pp. : 1471-1482

Informa Healthcare

Access to resources Recommend Favorite

A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 587-590

Informa Healthcare

Access to resources Recommend Favorite

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)

By Deng Xianming Choi Hwan Geun Buhrlage Sara J. Gray Nathanael S.

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 12, 2012-12 ,pp. : 1415-1426

Informa Healthcare

Access to resources Recommend Favorite

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

The Role of LRRK2 in Neurodegeneration of Parkinson Disease

Current Neuropharmacology, Vol. 16, Iss. 9, 2018-11 ,pp. : 1348-1357

Bentham Science Publishers

Access to resources Recommend Favorite